📢 Special Collection: "Expanding the Use of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: New Advances and Unmet Needs." Submit your research on ICI for HCC by November 18, 2024. Learn more and contribute: journals.sagepub.com/topic/collecti… #LiverCancer #OncologyResearch

Thought provoking keynote Raffaella Casolino World Health Organization (WHO) ASCO call to action to close gaps for global cancer innovation Need for access (testing, trials, drugs), education, data sharing #ASCOBT24

📊 Promising results for gumarontinib in MET overexpressing NSCLC patients! Editorial board members Yong Feng Yu and Shun Lu present their findings in this latest analysis. Read more: journals.sagepub.com/doi/full/10.11… #CancerResearch #LungCancer

Day 3 of ASCO Breakthrough 2024. Excellent keynote by Dr Shimon Sakaguchi. Shining light on potential of Tregs inhibition in addressing immune resistance. #ASCOBT24 ASCO Lillian Siu Melvin LK CHUA Kevin Chua Tingting Zhang Yu Fujiwara, MD Hidehito HORINOUCHI

#ASCOBT24 Final rapid oral session: so many high quality abstracts on #HealthTech #AI #innovation #RWD #realworldevidence Thanks to all the presenters for submitting your work to our meeting!

🌟Happening NOW #ASCOBT24 Day3⃣ 🔥Real World Evidence and Clinical Trials Beyond the Ivory Tower 🎯Rethinking Evidence Generation for Regulatory Approvals 🎙️Shaalan Beg MD MBA FASCO OncoAlert ASCO 日本臨床腫瘍学会（JSMO） conferences.asco.org/breakthrough/

🚀 Looking to advance your research career? The Sage Editorial Board Member Hub offers resources on becoming a peer reviewer and joining an Editorial Board. Ideal for both Early Career Researchers and experienced academics. Start here: us.sagepub.com/en-us/nam/edit… #CareerGrowth

📊 New study highlights the effectiveness of ferric carboxymaltose (FCM) over darbepoetin alfa (DA) in treating chemotherapy-induced anemia in esophagogastric or pancreaticobiliary cancer patients. Explore the findings: journals.sagepub.com/doi/full/10.11… #OncologyResearch #CancerCare

📊 A comprehensive network meta-analysis reveals how novel targeted therapies stack up against traditional treatments for relapsed/refractory chronic lymphocytic leukemia. Discover the latest findings in CLL treatment: journals.sagepub.com/doi/full/10.11… #Leukemia #CLL #OncologyResearch

📢 New research shows the sex-specific cardiovascular risks associated with #Osimertinib in older patients with #NSCLC. The study reveals increased heart failure risk in women and older adults, urging personalized care. Read more: journals.sagepub.com/doi/full/10.11… UT Austin Yan Liu, MD, PhD, RPVI, FACC

🔬 NEPC is a challenging variant of #ProstateCancer, but new research highlights emerging therapies like EZH2 inhibitors and DLL3-targeted therapies. Discover the future of NEPC treatment: journals.sagepub.com/doi/full/10.11… #CancerResearch #NEPC

💡 Insightful review & case report on #BreastCancer and #CervicalCancer in transgender men. Understand the risks, screening challenges, and gaps in current guidelines. Full article: journals.sagepub.com/doi/full/10.11… #LGBTQHealth #Oncology Eriseld Krasniqi Gennaro Ciliberto Francesco Lombardo

🔬 Can we overcome the barriers to CAR-T cell success in solid tumors? This article dives into how reprogramming the tumor microenvironment might enhance CAR-T effectiveness in high-grade gliomas: journals.sagepub.com/doi/full/10.11… #BrainCancer #Immunotherapy #CancerResearch